Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,933,300
  • Shares Outstanding, K 15,438
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,950 K
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.56
Trade MDGL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -3.35
  • Number of Estimates 8
  • High Estimate -2.92
  • Low Estimate -4.12
  • Prior Year -1.39
  • Growth Rate Est. (year over year) -141.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
113.76 +12.24%
on 09/30/20
136.13 -6.20%
on 10/14/20
+4.80 (+3.91%)
since 09/18/20
3-Month
98.65 +29.43%
on 08/06/20
136.13 -6.20%
on 10/14/20
+20.58 (+19.22%)
since 07/17/20
52-Week
56.82 +124.71%
on 04/02/20
136.13 -6.20%
on 10/14/20
+41.26 (+47.74%)
since 10/18/19

Most Recent Stories

More News
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has already exceeded the originally targeted enrollment of 700 patients in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients...

MDGL : 127.68 (+1.96%)
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress(TM) 2020

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress(TM) 2020, European Association for the Study of the Liver (EASL),...

MDGL : 127.68 (+1.96%)
Madrigal: 2Q Earnings Snapshot

WEST CONSHOHOCKEN, Pa. (AP) _ Madrigal Pharmaceuticals Inc. (MDGL) on Thursday reported a loss of $49 million in its second quarter.

MDGL : 127.68 (+1.96%)
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights:

MDGL : 127.68 (+1.96%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. - MDGL

NEW YORK, NY / ACCESSWIRE / June 17, 2020 / Levi & Korsinsky announces it has commenced an investigation of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) concerning possible breaches of fiduciary duty....

MDGL : 127.68 (+1.96%)
Madrigal: 1Q Earnings Snapshot

WEST CONSHOHOCKEN, Pa. (AP) _ Madrigal Pharmaceuticals Inc. (MDGL) on Thursday reported a loss of $36.1 million in its first quarter.

MDGL : 127.68 (+1.96%)
Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2020 financial results and highlights:

MDGL : 127.68 (+1.96%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. - MDGL

NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Levi & Korsinsky announces it has commenced an investigation of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) concerning possible breaches of fiduciary duty. To...

MDGL : 127.68 (+1.96%)
Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction

-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety...

MDGL : 127.68 (+1.96%)
Constellation Pharmaceuticals Announces Appointment of Dr. Richard Levy to Board of Directors

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Richard...

CELGZ : 0.47 (+2.15%)
MDGL : 127.68 (+1.96%)
NVS : 85.79 (-0.46%)
CNST : 22.71 (-1.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

2nd Resistance Point 131.69
1st Resistance Point 129.69
Last Price 127.68
1st Support Level 125.19
2nd Support Level 122.69

See More

52-Week High 136.13
Last Price 127.68
Fibonacci 61.8% 105.83
Fibonacci 50% 96.47
Fibonacci 38.2% 87.11
52-Week Low 56.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar